Skip to main content

Detlev Boison, PhD


Having a passion for translational research and for finding cures for intractable conditions that cause human suffrage and death, I seek to translate fundamental mechanisms of biochemistry and energy metabolism into novel therapeutic approaches for the treatment of neurological conditions. A major research effort is the development of metabolism-based therapies that enable disease modification in epilepsy and after traumatic brain injury. I graduated at the University of Köln, Germany, in 1994 with a PhD in Biochemistry. In 2005 I received the venia legendi (Habilitation) in Cellular Pharmacology from the University of Zurich, Switzerland, for my work on cell-based adenosine augmentation therapies for epilepsy. Over the past 25 years I have maintained a rigorous research program on translational adenosine research and have been continuously NIH funded since 2008. I have published over 152 papers with an h-index of 52 and have delivered over 130 invited lectures.



  • Graduate School (PhD in Biochemistry) – University of Koln, Germany


Research Interests:

  • The biochemistry and epigenetics of epilepsy
  • Focal adenosine-augmentation therapies to treat epilepsy
  • Therapies for epilepsy prevention
  • Brain regeneration after traumatic brain injury and stroke
  • Comorbidities in Neurology
  • The adenosine hypothesis of schizophrenia
  • Role of adenosine in cancer
  • Metabolic therapies


Publication Highlights: